RxDoctor Payments Data

Michael Cassell, MD

Retina Specialist · Kansas City, MONPI 1932107000

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Alcon at 37.6% of the total. 2025 is the largest year on record at $1,102, 9.0 times the $123 reported in 2019.

$2,788in general payments, 2019–2025

Across 89 payments — averaging $31.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Genentech USA, Inc.$366
  • Novartis$228
  • Sun Pharmaceutical Industries Inc.$202
  • Alimera Sciences, Inc.$190
  • ANI Pharmaceuticals, Inc.$186
  • plus $568 from 12 others
$386,279in research payments, 2019–2025

Across 16 payments — averaging $24,142 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$379K
  • Apellis Pharmaceuticals, Inc.$5K
  • ANI Pharmaceuticals, Inc.$3K

What the payments were for

  • Food & beverage$2,68396%
  • Entertainment$1044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,788 in reported general payments places this provider in the 55th percentile of 45 retina specialist providers in Missouri.

See all retina specialist providers in Missouri

Medicare billing

Part B allowed, 2024
$2,180,277
Medicare patients
1,210
Services billed
15,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate309$10,150
Ofloxacin189$2,064
Loteprednol Etabonate12$1,885
Ketorolac Tromethamine54$1,134
Timolol Maleate14$1,068
Eplerenone12$449
Latanoprost40$438
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$234
ErythromycinErythromycin Base13$114
Brimonidine Tartrate22$114

Paid to pharmacies, not to this prescriber.

Other retina specialist in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →